



ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260523014

Date: May 23, 2026

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India SCRIP CODE: 543275	To, National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India SYMBOL: ANURAS
---	--

Dear Sir/Madam,

Subject: Intimation of Press Release.

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release to be issued by Anupam Rasayan India Limited (the "Company") today i.e., May 23, 2026, regarding the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026, approved by the Board of Directors of the Company.

This Press Release will also be hosted on the website of the Company at www.anupamrasayan.com.

We request you to kindly take note the same.

Thanking you,

Yours Faithfully,

For Anupam Rasayan India Limited

Anand Desai
Managing Director
DIN: 00038442

Encl: As above



ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited **Q4 & FY26 Earnings Press Release**

Surat, May 23rd 2026: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India's leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and year ended March 31, 2026.

Particulars (Rs. In Mn)	Q4FY26	Q4FY25	YoY (%)	FY26	FY25	YoY (%)
Total Revenue	6,392	5,057	26%	23,836	14,485	65%
EBITDA	1,407	1,500	-6%	5,430	4,123	32%
<i>EBITDA Margin</i>	22%	30%		23%	28%	
PAT	560	629	-11%	2,222	1,600	39%

Consolidated Financial Highlights for year ended March 31, 2026:

- Total Revenue for FY26 was Rs 23,836 Mn as compared to Rs 14,485 Mn in FY25; up 65% YoY
- EBITDA (incl. other income) came in at Rs 5,430 Mn in FY26 as against Rs 4,123 Mn in FY25; up 32% YoY, translating into EBITDA margin of 23% for the full year.
- Profit After Tax stood at Rs 2,222 Mn in FY26 as compared to Rs 1,600 crores in FY25

Consolidated Financial Highlights for Quarter ended March 31, 2026:

- Total Revenue for Q4FY26 was at Rs 6,392 Mn as compared to Rs 5,057 Mn in Q4FY25; up 26 % YoY
- EBITDA (incl. other income) came in at Rs 1,407 Mn in Q4FY26 as against Rs 1,500 Mn in Q4FY25; down 6% YoY, translating into EBITDA margin of 22% for Q4FY26.
- Profit After Tax stood at Rs 560 Mn in Q4FY26 as compared to Rs 629 Mn in Q4FY25

Commenting on the performance, Mr. Anand Desai, Managing Director, Anupam Rasayan India Ltd., said "We are pleased to share that FY26 has been a landmark year for Anupam Rasayan, marked by strong operational execution, strategic expansion, and continued progress toward building a globally integrated specialty chemicals and CDMO platform. During the year, the Company achieved its highest-ever annual sales and operating cash flow performance, reflecting robust business momentum, operational efficiency, and strong cash generation. Growth was driven by commercialization of new products, addition of new multinational customers, and expanding engagements across key business verticals.

We continue to strengthen our presence in niche and complex chemistries where technical expertise and long qualification cycles create strong entry barriers and sustainable growth opportunities.

A key strategic milestone during the year was the successful acquisition of Jayhawk Fine Chemicals in the United States. Jayhawk delivered strong proforma revenue of US\$ 95Mn, reinforcing the strategic value of the acquisition and strengthening our global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. The acquisition also enhances our access to regulated markets and innovator customers across North America.

Additionally, we have signed a definitive agreement to acquire Bliss GVS Pharma which will further strengthen

our pharmaceutical value chain capabilities and is expected to create meaningful synergies across CDMO capabilities, product portfolio, and customer relationships.

Looking ahead, we remain well-positioned for the next phase of growth, supported by increasing contribution from Performance Materials and Pharma segment, a strong product pipeline, and expanding global customer engagements.”

About Anupam Rasayan Limited

Anupam Rasayan India Ltd (Anupam) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the specialty chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Polymer Additives. Anupam caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 185+ domestic and international customers. Anupam operates via its eight manufacturing facilities, with six facilities located in Gujarat, one in Tamil Nadu and one in U.S. with an aggregate installed capacity of ~2,00,000+ MT as of March 31, 2026. Anupam offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers.

For more information, please contact:

<u>Company Details</u>	<u>Investor Relations Advisors</u>
<p><u>Anupam Rasayan Ltd.</u></p>  <p>CIN: L24231GJ2003PLC042988 www.anupamrasayan.com</p>	<p>Strategic Growth Advisors Pvt. Ltd.</p> <p>SGA <u>Strategic Growth Advisors</u></p> <p>CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.net</p>

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Anupam Rasayan Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.